伦瓦提尼
医学
依维莫司
舒尼替尼
彭布罗利珠单抗
内科学
肾细胞癌
肿瘤科
癌症
免疫疗法
甲状腺癌
作者
Robert J. Motzer,B. Yа. Alekseev,Sun Young Rha,Camillo Porta,Masatoshi Eto,Thomas Powles,Viktor Grünwald,Thomas E. Hutson,Evgeny Kopyltsov,María José Méndez-Vidal,Vadim Kozlov,Anna Alyasova,Sung‐Hoo Hong,Anil Kapoor,Teresa Alonso Gordoa,Jaime R. Merchan,Eric Winquist,Pablo Maroto,Jeffrey C. Goh,Miso Kim
标识
DOI:10.1056/nejmoa2035716
摘要
Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).
科研通智能强力驱动
Strongly Powered by AbleSci AI